News from Vaxxinity and FLORIDA on a #collaboration to advance #vaccine development for #neurodegenerative diseases like #parkinsons and #alzheimers .
#vaccine nation #vaccine s #disease #florida
vaccinenation.org/therapeutic/va…

Under the agreement, @uf scientists will conduct preclinical studies exploring effects of vaccines for neurodegenerative diseases. See more: buff.ly/42zQokj

#parkinsons #parkinsons disease #parkinsons research #parkinsons treatment

Check out our executive chairman Lou Reese on Cheddar News Friday: Vaxxinity Wants to Bring Accessible Vaccines for Chronic Illness to Market.

cheddar.com/media/vaxxinit…

Vaxxinity Inc. will work with the University of Central Florida in Orlando to develop special new vaccines for astronauts that aim to prevent a common problem created during space exploration. Click for the details. bizjournals.com/orlando/news/2…

Could space travel research deliver a frailty vaccine?
Vaxxinity and UCF collaborate on muscle and bone wasting immunotherapies to benefit both space exploration and human longevity.
Lou Reese #longevity #space #research #vaccine
longevity.technology/news/could-spa…

Researchers return to Alzheimer's vaccines, buoyed by recent drug success reut.rs/3R3MQ5M

Our CEO, Mei Mei, has been recognized on the PharmaVoice 100 list as an inspiring leader in the life-sciences space!

pharmavoice.com/news/pharmavoi…

Join us online next Monday, 9/11 at 10am ET! You won’t want to miss the latest corporate update from our CEO. Watch live here: journey.ct.events/view/7f32ae28-…

Looking forward to presenting in September. Our H.C. Wainwright presentation will be broadcast live to the public. Tune in!

ir.vaxxinity.com/news-releases/…

Meet our Hidden Hero Rob Townley who work with some of our most complex and high risk projects at Maersk👊Learn more about how Rob helps bring our #purpose to life⭐
👉Watch the full video: youtu.be/i0KeZuW6wKw
#Maersk #HiddenHero #alltheway #Career

Jean-Cosme Dodart (Vaxxinity) discussed recently published trial findings on a novel vaccine that targets Alzheimer's disease and triggers the production of antibodies against toxic amyloid-ß peptides.

Watch here 👇 ow.ly/HBLP50PAV24

#ICYMI : Phase 1 trial results investigating UB-312 (Vaxxinity) revealed target engagement of aggregated alpha-synuclein in cerebrospinal fluid of patients with Parkinson disease.

Read more: ow.ly/21hk50PusiP

Treatment with an investigational anti- #amyloid therapeutic for adults with mild #AD was safe, efficacious and demonstrated a significant immune response up to 78 weeks, per a @Vaxxinity study published in eBioMedicine – The Lancet Discovery Science. bit.ly/3qqCAtU

Thought leader Jeffrey Cummings sums up our latest publication in The Lancet’s eBioMedicine – The Lancet Discovery Science about UB-311, the active vaccine candidate targeting beta-amyloid.

ir.vaxxinity.com/news-releases/…

Vaxxinity - Expansively Disrupting Medicine
Read more: bit.ly/3OnDFuF
#ChronicDiseaseVaccines

Did you miss last week's fireside chat on vaccines for #dementia ?

If so, you can find the inspiring & informative 30-minute conversation with ADI's wendy weidner, AC Immune's Andrea Pfeifer & Mei Mei Hu of Vaxxinity, on our YouTube channel. youtu.be/h7A93G0HVxU

Positive steps from Vaxxinity against #parkinsons disease as they continue to see results from their #vaccine UB-312.
#vaccine nation #vaccine s #parkinsons #disease #vaxxinity
vaccinenation.org/therapeutic/co…

Immune response triggered by UB-312 was seen in patients' CSF to target and engage alpha-synuclein clumps and slow their toxic buildup. buff.ly/44CI3Ni

#parkinsonssymptoms #parkinsonsdisease research #parkinsonsdisease #livingwithparkinsons

Another win for our UB-312 program! Read the full release here: ir.vaxxinity.com/news-releases/….

Another step forward in our mission to #democratizehealth !
parkinsonsnewstoday.com/news/vaccine-t…